Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 152

Similar articles for PubMed (Select 20195940)

1.

[On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].

Kassubek J, Büttner T, Reichmann H, Riederer P, Schulz JB, Wüllner U, Csoti I.

Fortschr Neurol Psychiatr. 2010 Mar;78 Suppl 1:S34-6. doi: 10.1055/s-0029-1245166. Epub 2010 Mar 1. Review. German.

PMID:
20195940
2.
3.
4.

The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy.

Elmer LW, Bertoni JM.

Expert Opin Pharmacother. 2008 Nov;9(16):2759-72. doi: 10.1517/14656566.9.16.2759 . Review.

PMID:
18937611
5.

Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.

Fernandez HH, Chen JJ.

Clin Neuropharmacol. 2007 May-Jun;30(3):150-68. Review.

PMID:
17545750
6.

Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.

Fernandez HH, Chen JJ.

Pharmacotherapy. 2007 Dec;27(12 Pt 2):174S-185S. Review.

PMID:
18041937
7.

Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.

Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G; Rasagiline Study Group.

Clin Neuropharmacol. 2000 Nov-Dec;23(6):324-30.

PMID:
11575866
8.

Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.

Guay DR.

Am J Geriatr Pharmacother. 2006 Dec;4(4):330-46. Review.

PMID:
17296539
9.
10.

Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.

Chen JJ, Ly AV.

Am J Health Syst Pharm. 2006 May 15;63(10):915-28. Review.

PMID:
16675649
11.

Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.

Schapira AH.

CNS Drugs. 2011 Dec 1;25(12):1061-71. doi: 10.2165/11596310-000000000-00000. Review.

PMID:
22133327
12.

Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.

Henchcliffe C, Schumacher HC, Burgut FT.

Expert Rev Neurother. 2005 Nov;5(6):811-21. Review.

PMID:
16274338
13.
14.
15.

Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.

Weinreb O, Amit T, Bar-Am O, Youdim MB.

Prog Neurobiol. 2010 Nov;92(3):330-44. doi: 10.1016/j.pneurobio.2010.06.008. Epub 2010 Jun 19. Review.

PMID:
20600573
16.

The role of rasagiline in the treatment of Parkinson's disease.

Leegwater-Kim J, Bortan E.

Clin Interv Aging. 2010 May 25;5:149-56. Review.

17.

[The use of a new MAO B inhibitor rasagiline in the treatment of motor fluctuations in Parkinson's disease].

Levin OS.

Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(9):91-6. Review. Russian. No abstract available.

PMID:
19004128
18.

Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.

Kupsch A, Sautter J, Götz ME, Breithaupt W, Schwarz J, Youdim MB, Riederer P, Gerlach M, Oertel WH.

J Neural Transm. 2001;108(8-9):985-1009.

PMID:
11716151
19.

Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.

Petzer JP, Castagnoli N Jr, Schwarzschild MA, Chen JF, Van der Schyf CJ.

Neurotherapeutics. 2009 Jan;6(1):141-51. doi: 10.1016/j.nurt.2008.10.035. Review.

PMID:
19110205
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk